Combination

Gainey McKenna & Egleston Investigates The Officers And Directors Of Embark Technology, Inc. (EMBK)

Retrieved on: 
Monday, September 26, 2022
District court, GLOBE, Company, Complaint, Combination, Securities Class Action, NASDAQ, Online shopping

A securities class action complaint is pending in the United States District Court for the Northern District of California (the Securities Class Action).

Key Points: 
  • A securities class action complaint is pending in the United States District Court for the Northern District of California (the Securities Class Action).
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • If you wish to discuss your rights or interests, please contact Thomas J. McKenna, Esq.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

Delwinds Insurance Acquisition Corp. Announces Anticipated Forward Purchase and Revised Backstop Agreements

Retrieved on: 
Monday, September 12, 2022
Registration statement, Risk, Investor, DWIN, FOXO, Suite, NYSE, Longevity, Sale, Company, Main Street, Acquisition, City centre, Special, Securities Act of 1933, Person, Combination company, Forward-looking statement, Technology, Business architecture, Combination, Finance Secretary (India), Science, Form, New, Prospectus, Proxy, SEC, GLOBE, One City Centre, Backstop, Communication, Register, Security (finance), Delwinder Singh

About Delwinds Insurance Acquisition Corp.

Key Points: 
  • About Delwinds Insurance Acquisition Corp.
    Delwinds is a special purpose blank check company formed to effectuate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
  • FOXO is a technology company aiming to make longevity science fundamental to life insurance.
  • Delwinds stockholders and other interested persons may obtain, without charge, more detailed information regarding directors and officers of Delwinds in the Registration Statement.
  • Neither Delwinds nor FOXO gives any assurance that either Delwinds or FOXO, or the combined company, will achieve its expectations.

Medicenna to Present at Investor and Scientific Conferences in September

Retrieved on: 
Thursday, September 8, 2022
Brain, EMA, Lotte New York Palace Hotel, CD25, GBM, NK, Centre International de Rencontres Mathématiques, Neoplasm, NASDAQ, CD122, Combination, MDNA, GLOBE, Bifunctional, Company, FDA, CEST, Growth, Online gambling, Pharmaceutical industry

Those interested in requesting a meeting with management should contact their H.C. Wainwright representative.

Key Points: 
  • Those interested in requesting a meeting with management should contact their H.C. Wainwright representative.
  • The conference is taking place at the Centre International de Confrences Sorbonne Universit in Paris, France from September 14 17, 2022.
  • Following the conference, slides from the oral presentation will be available on the Events and Presentations page of Medicennas website.
  • Medicennas early-stage BiSKITs program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically cold tumors.

Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, Immunoglobulin G, Shore, CEO, GLOBE, SEC, Investment, Database, Patient, VEGFR, Retina, DLA Piper, MD, Overalls, G1, Industry, Technology, Consultant, Patent, Diabetic retinopathy, Partnership, Safety, AMD, HarbourVest Global Private Equity, Initial public offering, ID, Combination, CG, Standard of care, Growth, DME, ASX, SPP, COVID-19, Program, Drug development, Â, Goal, Cooley LLP, Hope, Company, Twitter, NASDAQ, Intention, VEGF, Private Securities Litigation Reform Act, LinkedIn, Medicine, Solution, Pharmaceutical industry, Ranibizumab, Thakeham, Research

Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time.

Key Points: 
  • Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time.
  • "Opthea is thrilled to enter this strategic arrangement with Launch Tx, and to receive funding from world-leading investors in Carlyle and Abingworth.
  • At Launch Tx, we are committed to working with pharma and biotech partners to expedite late-stage drug development programs.
  • Opthea currently is enrolling patients for its two ongoing concurrent pivotal Phase 3 clinical trials for the treatment of wet AMD.

CENAQ Energy Corp. Announces Extension of Deadline to Complete Business Combination

Retrieved on: 
Friday, August 12, 2022
U.S. Securities and Exchange Commission, Securities Act of 1933, Risk, CEO, GLOBE, CFO, Failure, Growth, Securities Exchange Act of 1934, SEC, LLC, Security (finance), Annual report, Communication, Acquisition, Extension, NASDAQ, THE, Combination, Bluescape

CENAQ must complete an initial business combination within 12 months from the closing of its initial public offering on August 17, 2021 (the Initial Combination Period), which may be extended by three months if it files a proxy statement, registration statement or similar filing for an initial business combination within the Initial Combination Period.

Key Points: 
  • CENAQ must complete an initial business combination within 12 months from the closing of its initial public offering on August 17, 2021 (the Initial Combination Period), which may be extended by three months if it files a proxy statement, registration statement or similar filing for an initial business combination within the Initial Combination Period.
  • The Extension provides CENAQ with additional time to complete its initial business combination.
  • CENAQ is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
  • In connection with the proposed business combination, CENAQ has filed with the SEC a preliminary proxy statement.

Renewable Gasoline Company Bluescape Clean Fuels, LLC to Become Publicly Traded on NASDAQ via Business Combination with CENAQ Energy Corp. and be renamed Verde Clean Fuels, LLC

Retrieved on: 
Friday, August 12, 2022
Carbon, U.S. Securities and Exchange Commission, Renewable Fuel Standard (United States), CEO, GLOBE, Business architecture, Failure, SEC, Investment, Board, Annual report, Communication, Securities Act of 1933, Securities Exchange Act of 1934, Risk, CFO, Technology, Imperial Capital, WM, THE, Combination, Growth, LLC, LLP, Gasoline, Acquisition, Time, Management, NYSE, Capital, Emission intensity, Waste management, RFS, PIPE, NASDAQ, Ownership, BCF, Renewable energy, Security (finance)

Upon closing of the Business Combination, the combined company will be named Verde Clean Fuels, Inc. (Verde Clean Fuels), and is expected to become publicly listed on the NASDAQ under the symbol VGAS.

Key Points: 
  • Upon closing of the Business Combination, the combined company will be named Verde Clean Fuels, Inc. (Verde Clean Fuels), and is expected to become publicly listed on the NASDAQ under the symbol VGAS.
  • BCFs product is a proven drop in replacement for hydrocarbon-based gasoline and provides significant environmental and economic advantages as compared to traditional gasoline.
  • Partnering with BCF in the creation of Verde Clean Fuels fits perfectly with our goal of gaining exposure to an energy transition opportunity.
  • The proceeds will be used to fund Verde Clean Fuels initial facility as well as future renewable gasoline facilities currently under development.

Kymanox Announces First Kymanox Executive Advisor: Fran DeGrazio

Retrieved on: 
Thursday, August 11, 2022
Cell, Industry, Combination, GLOBE, CEO, Triangle Park (Quezon City), Cabrini University, Knowledge, Ed Smith, Compliance, Marketing, List of life sciences, Engineering, Biotechnology, Parenteral Drug Association, West Pharmaceutical Services, KEA, Gene therapy, PDA, Organization, Interior design, Management, Pharmaceutical industry, Chemistry

Philadelphia, Pennsylvania and Research Triangle Park, North Carolina, USA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kymanox Corporation (Kymanox), a professional services provider exclusively serving the Life Science industry, is honored to announce Fran DeGrazio to the newly formed Kymanox Executive Advisors team.

Key Points: 
  • Philadelphia, Pennsylvania and Research Triangle Park, North Carolina, USA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kymanox Corporation (Kymanox), a professional services provider exclusively serving the Life Science industry, is honored to announce Fran DeGrazio to the newly formed Kymanox Executive Advisors team.
  • Fran DeGrazio recently received the Edward Smith Packaging Science Award at the 2022 PDA Annual Meeting in Dallas for outstanding lifetime contributions in packaging for the pharmaceutical industry.
  • Michael Denzer, a key executive at Kymanox, states, Our mission is to help the industry deliver critical medicines to humanity quickly and reliably.
  • Fran DeGrazio, as our first Kymanox Executive Advisor (KEA), will solidify our strategic professional advisement services and further establish Kymanox as an industry thought leader, said Stephen M. Perry, CEO and Founder at Kymanox.

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

Retrieved on: 
Thursday, August 11, 2022
FDA, Death, Woman, Fulvestrant, The New England Journal of Medicine, Everolimus, Risk, Emergency Use Authorization, Trial of the century, Article 18 of the European Convention on Human Rights, GLOBE, FC2, Breast, Standard of care, EUA, Clinical, High Risk, COVID, Sale, Infection, Medicines and Healthcare products Regulatory Agency, Medicine, CDK, Enobosarm, Government, Patient, Review, COVID-19, Company, Lilly, Breast cancer, European Medicines Agency, Expression, Safety, Metastatic breast cancer, Capsule, NASDAQ, U.S. FDA, Â, MHRA, SERM, WHO, Fast Track, Combination, AR, Pharmaceutical industry, Reinsurance, Cryptocurrency, Medical device, Birth control, Verus Pharmaceuticals

--Company Prepares for U.S. and Ex-U.S. Commercial Launches if Emergency Authorizations Are Granted--

Key Points: 
  • By reducing deaths in hospitalized COVID-19 patients, sabizabulin has great potential to play a critical role in the battle against COVID-19.
  • The Company has Completed a Positive Phase 3 COVID-19 Study in Hospitalized Moderate to Severe COVID-19 Patients at High Risk for ARDS.
  • On July 25, 2022, the UKs Medicines and Healthcare Products Regulatory Agency (MHRA) informed the Company that the sabizabulin marketing authorization application will receive expedited review.
  • On July 27, 2022, the European Medicines Agencys Emergency Task Force initiated the review of sabizabulin treatment for hospitalized COVID-19 patients for emergency use in European Union countries.

Pono Capital Corp Announces Termination of Merger Agreement with Benuvia, Inc.

Retrieved on: 
Wednesday, August 10, 2022
Industry, Forward-looking statement, GLOBE, SEC, Pono, Company, Acquisition, Risk, PONO, NASDAQ, Nasdaq, Combination, Security (finance)

Honolulu, Hawaii, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pono Capital Corp (NASDAQ: PONO) (the Company or Pono), a special purpose acquisition company, announced today that it has terminated its previously announced agreement and plan of merger (the Business Combination Agreement) with Benuvia, Inc. (Benuvia), by mutual agreement of all relevant parties.

Key Points: 
  • Honolulu, Hawaii, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pono Capital Corp (NASDAQ: PONO) (the Company or Pono), a special purpose acquisition company, announced today that it has terminated its previously announced agreement and plan of merger (the Business Combination Agreement) with Benuvia, Inc. (Benuvia), by mutual agreement of all relevant parties.
  • As a result, Pono will seek an alternative business combination.
  • Pono is a blank check company formed for the purpose of effecting a business combination with one or more businesses.
  • Ponos securities are listed on Nasdaq under the ticker symbols PONOU, PONO and PONOW.

Agenus Provides Corporate Update and Second Quarter 2022 Financial Report

Retrieved on: 
Tuesday, August 9, 2022
ESMO, IO, Survival, MSS, CRC, GLOBE, ORR, CD137, Investment, Hope, Cancer, Patient, Pancreatic cancer, DCR, Therapy, Infection, Doctor of Philosophy, NASDAQ, Melanoma, HCR, Colorectal cancer, Financial toxicity, Oncology, GI, Combination, Pharmaceutical industry, Online gambling, Bank

LEXINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, todayprovided a corporate update and reported financial results for the second quarter of 2022.

Key Points: 
  • LEXINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, todayprovided a corporate update and reported financial results for the second quarter of 2022.
  • We ended our second quarter 2022 with a cash and short-term investment balance of $238 million as compared to $263 million and $307 million on March 31, 2022, and December 31, 2021, respectively.
  • For the second quarter ended June 30, 2022, our cash used in operations was $43 million compared to $56 million for the same period in 2021.
  • Non-cash operating expenses for the second quarter ended June 30, 2022, were $19 million compared to $30 million for the second quarter of 2021.